Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

Candor Announces Acquisition of Tenex


ROME, Ga. and NEW YORK, Dec. 16, 2017 /PRNewswire/ -- Candor, a technology and marketplace company specializing in pairing consumers with top health plans, announces the acquisition of Tenex, a comprehensive software development company. Candor is strengthened by the transaction and now has the ability to enhance technological support.

Candor enables access to truly flexible benefits and wellness solutions based on the specific needs of consumers and offers Prosper Benefitstm at the True Cost of Caretm. The Candor app simplifies the enrollment process and automates the user experience.

John Good, COO of Candor, explains, "We demonstrate the True Cost of Care. In other words, there are healthcare plans that have higher negotiated rates for the same procedures. These plans, which we eliminate, are masked by similar copays, deductibles and out-of-pocket expenses. We feel they are deceptive and strive to present plans with integrity."

Tenex builds scalable, maintainable, robust code. They have drawn on the successes of their experiences at enterprises (like Vistaprint and Amazon) and startups (like Financial Diligence Networks) to develop a program that maximizes the ability to build a successful product.

Josh Jordan, CEO of Tenex says, "Tenex has always been about solving the hardest problems in the business. Candor is out to change the world through technology, and #democratizehealthinsurance by changing how people think about their coverage. That demands a phenomenal product. Keeping quality impossibly high, while iterating quickly is paramount. This is what we do every day, and we feel it is a perfect fit! We're still Tenex developers and we always will be, but now we get to come along for the journey with our new family at Candor."

About Candor

Candor is a technology and marketplace company providing powerful analytics, tools, and methodologies to benefit Agencies, Carriers, and Healthcare Providers. We are the health companion that enables Americans to access the information and solutions they need to achieve a state of complete independence, success and wellbeing.

For more information visit https://candor.insurance.

About Tenex
Tenex solves the hardest technology problems the industry has to offer. We build scalable, maintainable, robust code that solves business problems. We aren't interested in perfect design or perfect code, we're interested in adding value.

For more information visit https://www.crunchbase.com/organization/tenex-developers.

Candor PR contact
Merissa Rood
[email protected]

SOURCE Candor USA


These press releases may also interest you

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...



News published on and distributed by: